Marco Genua1, Silvia D'Alessio2, Javier Cibella2, Alessandro Gandelli2, Emanuela Sala2, Carmen Correale2, Antonino Spinelli3, Vincenzo Arena4, Alberto Malesci1, Sergio Rutella4, Victoria A Ploplis5, Stefania Vetrano2, Silvio Danese2. 1. IBD Center, Humanitas Clinical and Research Center, Rozzano, Italy Department of Translational Medicine, University of Milan, Milan, Italy. 2. IBD Center, Humanitas Clinical and Research Center, Rozzano, Italy. 3. Department of Translational Medicine, University of Milan, Milan, Italy Department of Surgery-IBD Surgery Unit, Humanitas Clinical and Research Center, Rozzano, Italy. 4. Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. 5. W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA.
Abstract
OBJECTIVE: Inflammation plays crucial roles in the pathogenesis of several chronic inflammatory disorders, including Crohn's disease (CD) and UC, the two major forms of IBD. The urokinase plasminogen activator receptor (uPAR) exerts pleiotropic functions over the course of both physiological and pathological processes. uPAR not only has a key role in fibrinolysis but also modulates the development of protective immunity. Additionally, uPAR supports extracellular matrix degradation and regulates cell migration, adhesion and proliferation, thus influencing the development of inflammatory and immune responses. This study aimed to evaluate the role of uPAR in the pathogenesis of IBD. DESIGN: The functional role of uPAR was assessed in established experimental models of colitis. uPAR deficiency effects on cytokine release, polarisation and bacterial phagocytosis were analysed in colonic macrophages. uPAR expression was analysed in surgical specimens collected from normal subjects and patients with IBD. RESULTS: In mice, uPAR expression is positively regulated as colitis progresses. uPAR-KO mice displayed severe inflammation compared with wild-type littermates, as indicated by clinical assessment, endoscopy and colon histology. The absence of uPAR led to an increased production of inflammatory cytokines by macrophages that showed an M1 polarisation and impaired phagocytosis. In human IBD, CD68(+) macrophages derived from the inflamed mucosa expressed low levels of uPAR. CONCLUSIONS: These findings point to uPAR as an essential component of intestinal macrophage functions and unravel a new potential target to control mucosal inflammation in IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE:Inflammation plays crucial roles in the pathogenesis of several chronic inflammatory disorders, including Crohn's disease (CD) and UC, the two major forms of IBD. The urokinase plasminogen activator receptor (uPAR) exerts pleiotropic functions over the course of both physiological and pathological processes. uPAR not only has a key role in fibrinolysis but also modulates the development of protective immunity. Additionally, uPAR supports extracellular matrix degradation and regulates cell migration, adhesion and proliferation, thus influencing the development of inflammatory and immune responses. This study aimed to evaluate the role of uPAR in the pathogenesis of IBD. DESIGN: The functional role of uPAR was assessed in established experimental models of colitis. uPARdeficiency effects on cytokine release, polarisation and bacterial phagocytosis were analysed in colonic macrophages. uPAR expression was analysed in surgical specimens collected from normal subjects and patients with IBD. RESULTS: In mice, uPAR expression is positively regulated as colitis progresses. uPAR-KO mice displayed severe inflammation compared with wild-type littermates, as indicated by clinical assessment, endoscopy and colon histology. The absence of uPAR led to an increased production of inflammatory cytokines by macrophages that showed an M1 polarisation and impaired phagocytosis. In human IBD, CD68(+) macrophages derived from the inflamed mucosa expressed low levels of uPAR. CONCLUSIONS: These findings point to uPAR as an essential component of intestinal macrophage functions and unravel a new potential target to control mucosal inflammation in IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Michelle A Sugimoto; Ana Luíza C Ribeiro; Bruno R C Costa; Juliana P Vago; Kátia M Lima; Fernanda S Carneiro; Mylena Maira O Ortiz; Graziele Letícia N Lima; Aline A F Carmo; Renata M Rocha; Denise A Perez; Alessandra C Reis; Vanessa Pinho; Lindsey A Miles; Cristiana C Garcia; Mauro M Teixeira; Lirlândia P Sousa Journal: Blood Date: 2017-03-20 Impact factor: 22.113
Authors: Seong Beom Ahn; Charles Chan; Owen F Dent; Abidali Mohamedali; Sun Young Kwun; Candice Clarke; Julie Fletcher; Pierre H Chapuis; Edouard C Nice; Mark S Baker Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: Juliana P Vago; Michelle A Sugimoto; Kátia M Lima; Graziele L Negreiros-Lima; Nagyung Baik; Mauro M Teixeira; Mauro Perretti; Robert J Parmer; Lindsey A Miles; Lirlândia P Sousa Journal: Front Immunol Date: 2019-06-28 Impact factor: 7.561
Authors: Sven H Loosen; Frank Tacke; Niklas Püthe; Marcel Binneboesel; Georg Wiltberger; Patrick H Alizai; Jakob N Kather; Pia Paffenholz; Thomas Ritz; Alexander Koch; Frank Bergmann; Christian Trautwein; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde Journal: Carcinogenesis Date: 2019-08-22 Impact factor: 4.944
Authors: Wayne A Schroder; Thiago D Hirata; Thuy T Le; Joy Gardner; Glen M Boyle; Jonathan Ellis; Eri Nakayama; Dilan Pathirana; Helder I Nakaya; Andreas Suhrbier Journal: Sci Rep Date: 2019-08-27 Impact factor: 4.379
Authors: Sven H Loosen; Frank Tacke; Marcel Binnebosel; Catherine Leyh; Mihael Vucur; Florian Heitkamp; Wenzel Schoening; Tom F Ulmer; Patrick H Alizai; Christian Trautwein; Alexander Koch; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde Journal: Oncotarget Date: 2018-06-05